HLS Therapeutics (TSE:HLS) Hits New 1-Year Low – Time to Sell?

HLS Therapeutics Inc. (TSE:HLS)’s share price hit a new 52-week low during trading on Friday. The company traded as low as C$3.51 and last traded at C$3.65, with a volume of 78,476 shares trading hands. The stock had previously closed at C$3.70.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on HLS. Canaccord Genuity Group raised HLS Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 13th. Raymond James Financial raised HLS Therapeutics from an “outperform” rating to a “strong-buy” rating and raised their price objective for the company from C$7.00 to C$8.00 in a research note on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Strong Buy” and an average target price of C$8.00.

HLS Therapeutics Price Performance

The firm has a market cap of C$114.46 million, a P/E ratio of -13.70 and a beta of -0.52. The stock’s 50 day simple moving average is C$4.11 and its 200 day simple moving average is C$4.29. The company has a debt-to-equity ratio of 75.86, a quick ratio of 1.01 and a current ratio of 1.05.

HLS Therapeutics (TSE:HLS) last released its quarterly earnings data on Thursday, November 12th. The company reported C($0.10) earnings per share for the quarter. HLS Therapeutics had a negative return on equity of 14.39% and a negative net margin of 15.26%. The business had revenue of C$20.15 million for the quarter. Research analysts anticipate that HLS Therapeutics Inc. will post -0.12 EPS for the current year.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.